Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants

被引:48
|
作者
Jervis, Sarah [1 ]
Song, Honglin [2 ]
Lee, Andrew [1 ]
Dicks, Ed [2 ]
Tyrer, Jonathan [2 ]
Harrington, Patricia [2 ]
Easton, Douglas F. [1 ,2 ]
Jacobs, Ian J. [3 ,4 ]
Pharoah, Paul P. D. [1 ,2 ]
Antoniou, Antonis C. [1 ]
机构
[1] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ & Primary Care, Cambridge, England
[2] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge, England
[3] Univ Manchester, Fac Med & Human Sci, Inst Human Dev, Manchester, Lancs, England
[4] Manchester Acad Hlth Sci, Manchester, Lancs, England
关键词
Genetic screening; counselling; Genetic epidemiology; Obstetrics and Gynaecology; Oncology; Other oncology; BREAST; HISTORY; BRCA1; WOMEN; METAANALYSIS; MUTATIONS; MORTALITY; BRIP1; MODEL;
D O I
10.1136/jmedgenet-2013-102015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Family history is one of the most important risk factors for epithelial ovarian cancer (EOC). Little is known, however, on how EOC familial relative risks (FRRs) vary by factors such as tumour subtype or the combined effects of common EOC susceptibility alleles. In addition, no data currently exist on the FRRs associated with EOC after exclusion of BRCA1 or BRCA2 mutation carriers. Methods EOC FRRs were computed from observed EOCs in relatives of 1548 patients with EOC recruited between 1999 and 2010 from a population-based cohort study with known BRCA1 and BRCA2 mutation status and tumour subtype, compared with the number expected in the general population. Results The EOC FRR to all first-degree relatives was estimated to be 2.96 (95% CI 2.35 to 3.72) but there was no evidence of difference in the FRRs for mothers, sisters and daughters. There was significant evidence that the FRR for relatives of patients with EOC diagnosed under age 50 years is higher than that for older patients (4.72 (95% CI 3.21 to 6.95) and 2.53 (95% CI 1.91 to 3.35), p-diff=0.0052) and a suggestion that the FRR in relatives of patients with serous disease is higher than that for non-serous tumours (3.64 (95% CI 2.72 to 4.87) and 2.25 (95% CI 1.56 to 3.26), p-diff=0.0023). The FRR to relatives of cases without a deleterious mutation in BRCA1 or BRCA2 was estimated to be over twice that of the general population (2.24 (95% CI 1.71 to 2.94)). BRCA1 and BRCA2 mutations were estimated to account for about 24% of the EOC FRR to first-degree relatives. FRRs were found to increase with increasing polygenic risk score of the index patient, although the trend was not significant. Conclusions These estimates could be useful in the counselling of relatives of patients with ovarian cancer.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 50 条
  • [1] Breast cancer susceptibility variants alter risk in familial ovarian cancer
    A. Latif
    H. J. McBurney
    S. A. Roberts
    F. Lalloo
    A. Howell
    D. G. Evans
    W. G. Newman
    [J]. Familial Cancer, 2010, 9 : 503 - 506
  • [2] Breast cancer susceptibility variants alter risk in familial ovarian cancer
    Latif, A.
    McBurney, H. J.
    Roberts, S. A.
    Lalloo, F.
    Howell, A.
    Evans, D. G.
    Newman, W. G.
    [J]. FAMILIAL CANCER, 2010, 9 (04) : 503 - 506
  • [3] Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer
    Pavanello, Marina
    Chan, Isaac H. Y.
    Ariff, Amir
    Pharoah, Paul D. P.
    Gayther, Simon A.
    Ramus, Susan J.
    [J]. CANCERS, 2020, 12 (10) : 1 - 23
  • [4] Cancer risks in women with 2 breast or ovarian cancers: Clues to genetic cancer susceptibility
    Evans, HS
    Lewis, CM
    Robinson, D
    Bell, CMJ
    Moller, H
    Hodgson, SV
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (05) : 758 - 759
  • [5] Association Study of Prostate Cancer Susceptibility Variants with Risks of Invasive Ovarian, Breast, and Colorectal Cancer
    Song, Honglin
    Koessler, Thibaud
    Ahmed, Shahana
    Ramus, Susan J.
    Kjaer, Susanne Kruger
    DiCioccio, Richard A.
    Wozniak, Eva
    Hogdall, Estrid
    Whittemore, Alice S.
    McGuire, Valerie
    Ponder, Bruce A. J.
    Turnbull, Clare
    Hines, Sarah
    Rahman, Nazneen
    Eeles, Rosalind A.
    Easton, Douglas F.
    Gayther, Simon A.
    Dunning, Alison M.
    Pharoah, Paul D. P.
    [J]. CANCER RESEARCH, 2008, 68 (21) : 8837 - 8842
  • [6] Subtypes of Ovarian Cancer and Ovarian Cancer Screening
    Koshiyama, Masafumi
    Matsumura, Noriomi
    Konishi, Ikuo
    [J]. DIAGNOSTICS, 2017, 7 (01):
  • [7] Genetic susceptibility to breast and ovarian cancer
    Skolnick, MH
    Frank, T
    ShattuckEidens, D
    Tavtigian, S
    [J]. PATHOLOGIE BIOLOGIE, 1997, 45 (03): : 245 - 249
  • [8] Genetic susceptibility to breast and ovarian cancer
    Hodgson, SV
    [J]. CANCER GENE THERAPY, 1997, 4 (01) : 67 - 68
  • [9] Psychological Sequelae of Ovarian Cancer Screening and Genetic Testing for Ovarian Cancer Susceptibility
    Howard, A. Fuchsia
    Pirotta, Marie
    Balneaves, Lynda G.
    [J]. CURRENT WOMENS HEALTH REVIEWS, 2011, 7 (04) : 358 - 366
  • [10] Novel genetic variants in miR-191 gene and familial ovarian cancer
    Jie Shen
    Richard DiCioccio
    Kunle Odunsi
    Shashikant B Lele
    Hua Zhao
    [J]. BMC Cancer, 10